HC Wainwright Raises Denali Therapeutics (NASDAQ:DNLI) Price Target to $87.00

Denali Therapeutics (NASDAQ:DNLI) had its target price raised by investment analysts at HC Wainwright from $80.00 to $87.00 in a research note issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 425.36% from the stock’s current price. HC Wainwright also issued estimates for Denali Therapeutics’ Q1 2025 earnings at ($0.69) EPS, Q2 2025 earnings at ($0.69) EPS, Q3 2025 earnings at ($0.70) EPS and Q4 2025 earnings at ($0.71) EPS.

Several other research analysts also recently commented on DNLI. Jefferies Financial Group increased their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft assumed coverage on Denali Therapeutics in a research note on Tuesday, February 11th. They issued a “buy” rating and a $31.00 price objective for the company. Baird R W raised Denali Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 7th. The Goldman Sachs Group reduced their price objective on Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Finally, Stifel Nicolaus raised Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price objective for the company in a research note on Monday, December 16th. Two research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.42.

Denali Therapeutics Price Performance

Shares of DNLI stock opened at $16.56 on Friday. The company has a market cap of $2.38 billion, a price-to-earnings ratio of -6.00 and a beta of 1.43. The stock has a 50 day simple moving average of $21.29 and a 200-day simple moving average of $24.55. Denali Therapeutics has a 1-year low of $14.56 and a 1-year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.08. Analysts anticipate that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Steve E. Krognes sold 3,339 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total transaction of $69,484.59. Following the completion of the transaction, the director now directly owns 25,757 shares in the company, valued at approximately $536,003.17. This represents a 11.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Vicki L. Sato sold 3,080 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the transaction, the director now owns 107,976 shares of the company’s stock, valued at approximately $2,257,778.16. This represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 47,940 shares of company stock valued at $973,442 in the last three months. 7.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Denali Therapeutics

A number of hedge funds have recently modified their holdings of DNLI. FMR LLC boosted its holdings in Denali Therapeutics by 3,234.3% during the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company’s stock valued at $228,128,000 after acquiring an additional 7,596,508 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Denali Therapeutics by 63.2% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock valued at $109,223,000 after acquiring an additional 1,451,770 shares during the period. Norges Bank purchased a new position in Denali Therapeutics during the 4th quarter valued at about $21,717,000. Wellington Management Group LLP boosted its holdings in Denali Therapeutics by 9.2% during the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock valued at $312,491,000 after acquiring an additional 903,683 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in Denali Therapeutics by 7.6% during the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company’s stock valued at $244,993,000 after acquiring an additional 843,996 shares during the period. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.